United Therapeutics
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 week.
- Recent price momentum is +12.0% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 8.4% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Anonymous reader poll. Unscientific, not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 541.51
- Open
- 545.49
- Day range
- 530.18 - 551.77
- Avg price
- 535.36
- Volume
- 668.25K
- Turnover
- 357.76M
- Turnover ratei
- 1.70%
- Volume ratioi
- 0.96
- Amplitudei
- 3.99%
- 52-week rangei
- 409.07 - 609.35
Valuation
- P/Ei
- 19.14
- P/E (TTM)i
- 19.10
- P/Bi
- 3.57
- EPSi
- 27.86
- Book value / shi
- 149.22
- Net profit
- 1.19B
- Net assets
- 6.40B
Share structure
- Market cap
- 22.87B
- Float capi
- 20.91B
- Shares out
- 42.89M
- Float sharesi
- 39.21M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
12.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+24.05M net over the window
Short interest
- Shares short
- 3.60M
- % of floati
- 8.39%
- Days to coveri
- 3.61
- As of
- 2026-09-30
Frequently asked questions
What is the current stock price of United Therapeutics (UTHR)?
United Therapeutics last traded at 533.12. The quote on this page refreshes every few seconds while US markets are open.
What is United Therapeutics's market cap?
About 22.87B.
What is the P/E ratio of United Therapeutics?
The trailing twelve-month P/E is 19.10, above its own 5-year average of 15.98 — toward the top of its historical range (89.16% percentile). See the Valuation tab for the full history.
Does United Therapeutics pay a dividend?
United Therapeutics does not currently pay a regular dividend.
Is United Therapeutics a buy according to analysts?
The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 643.00, which implies 20.6% upside from the current price. This is not investment advice.
What is United Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates United Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-16 19:30:05 · For reference only, not investment advice and not tailored to your situation.
United Therapeutics discussion 0 comments